217 WORDS, 90 SECONDS



NEWS OF HEALTH

For years, Nicole DiCamillo's cancer prevented her from participating in Normal Activities, like playing with her kids or even cooking family dinners.

"You're down, and you're in pain, and you can't be with your family."]

That all changed when she started to get infusions of Lutathera, a radiotherapeutic that targeted her tumors.

"With Lutathera, I'm able to just play with my kids, and be a mom, and cook dinner. I have a real life. I do. I really do have a real life." [

A NEW REPORT FROM THE AMERICAN ASSOCIATION FOR CANCER RESEARCH HIGHLIGHTS HOW FEDERAL FUNDING OF BIOMEDICAL SCIENCE IS DRIVING THE DEVELOPMENT OF NEW AND EVEN MORE EFFECTIVE WAYS TO PREVENT, DETECT, DIAGNOSE AND TREAT CANCER. IN THE TWELVE MONTHS ENDING JULY 31, 2018, TWENTY-TWO TREATMENTS FOR CANCER WERE NEWLY APPROVED BY THE F-D-A, OR HAD THEIR USE EXPANDED TO MORE FORMS OF THE DISEASE. THOSE APPROVALS INCLUDED TWO THAT ARE THE FIRST IN A REVOLUTIONARY TYPE OF IMMUNOTHERAPY, CALLED CAR T-CELL THERAPY. ADD TWO TARGETED RADIO-THERAPEUTICS FOR TREATING CERTAIN PATIENTS WITH NEURO-ENDOCRINE TUMORS, LIKE NICOLE.

A-A-C-R President Doctor Elizabeth Jaffee talks about the New Report.

"We are in an unprecedented time of progress. We're rapidly moving these new discoveries into real treatments for patients. Federal investment in cancer research is critical to cancer care."